Inhibition of platelet function by low-dose plain and micro-encapsulated acetylsalicylic acid.
The effect of two acetylsalicylic acid (ASA) formulations, plain (Magnyl) and micro-encapsulated (Globentyl), on platelet aggregation, thromboxane formation, and bleeding time was studied in 12 healthy volunteers in a randomized double-blind cross-over study. All subjects were treated with Magnyl and Globentyl (75 mg daily) in periods of 2 weeks, separated by a wash-out period of 2 weeks. Both drugs significantly depressed platelet aggregation and thromboxane formation and prolonged bleeding time without difference in mode of action of the drugs. It is concluded that significant inhibition of platelet activity may be achieved by low-dose ASA treatment with micro-encapsulated as well as with plain formulations.
D000328:Adult; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000494:pharmacology; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology*; D001760:Bleeding Time; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D004311:Double-Blind Method; D004339:Drug Compounding; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D010979:Platelet Function Tests; D013607:Tablets; D013929:Thromboxane B2 / Q000096:biosynthesis*
D001095:Arachidonic Acids; D013607:Tablets; D016718:Arachidonic Acid; D013929:Thromboxane B2; D001241:Aspirin